JPH08504210A - 結合生物活性ペプチドを使用した敗血症性ショックの治療 - Google Patents

結合生物活性ペプチドを使用した敗血症性ショックの治療

Info

Publication number
JPH08504210A
JPH08504210A JP6514320A JP51432094A JPH08504210A JP H08504210 A JPH08504210 A JP H08504210A JP 6514320 A JP6514320 A JP 6514320A JP 51432094 A JP51432094 A JP 51432094A JP H08504210 A JPH08504210 A JP H08504210A
Authority
JP
Japan
Prior art keywords
peptide
amino acid
hydrophilic
sequence
basic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP6514320A
Other languages
English (en)
Japanese (ja)
Inventor
ムクタ ヘンディー
メーナ ラオ
タフィー ジェー． ウイリアムス
Original Assignee
マガイニン ファーマシューティカルズ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マガイニン ファーマシューティカルズ，インク． filed Critical マガイニン ファーマシューティカルズ，インク．
Publication of JPH08504210A publication Critical patent/JPH08504210A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/463—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from amphibians
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP6514320A 1992-12-07 1993-12-06 結合生物活性ペプチドを使用した敗血症性ショックの治療 Pending JPH08504210A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98744392A 1992-12-07 1992-12-07
US987,443 1992-12-07
PCT/US1993/011841 WO1994013697A1 (fr) 1992-12-07 1993-12-06 Traitement de chocs septiques au moyen de peptides biologiquement actifs conjugues

Publications (1)

Publication Number Publication Date
JPH08504210A true JPH08504210A (ja) 1996-05-07

Family

ID=25533260

Family Applications (1)

Application Number Title Priority Date Filing Date
JP6514320A Pending JPH08504210A (ja) 1992-12-07 1993-12-06 結合生物活性ペプチドを使用した敗血症性ショックの治療

Country Status (5)

Country Link
EP (1) EP0672053A1 (fr)
JP (1) JPH08504210A (fr)
AU (1) AU5741794A (fr)
CA (1) CA2151046A1 (fr)
WO (1) WO1994013697A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025037729A1 (fr) * 2023-08-14 2025-02-20 건국대학교 산학협력단 Peptide cécropine isolé de larves de trichoplusia ni et son utilisation pour le traitement de la sepsie, d'une infection bactérienne ou de maladies inflammatoires

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348445B1 (en) 1992-06-01 2002-02-19 Magainin Pharmaceuticals, Inc. Biologically active peptides with reduced toxicity in animals and a method for preparing same
US5847047A (en) * 1993-06-22 1998-12-08 E. I. Du Pont De Nemours And Company Antimicrobial composition of a polymer and a peptide forming amphiphilic helices of the magainin-type
AU693518B2 (en) * 1994-01-18 1998-07-02 Magainin Pharmaceuticals, Inc. Ion-channel forming amphiphilic peptides having n-terminal modifications
GB9504761D0 (en) * 1995-03-09 1995-04-26 Unilever Plc Amphiphilic peptide and analogs thereof
KR100417183B1 (ko) * 1995-03-22 2004-05-31 헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신 유기시아닐화제로활성화된가용성탄수화물을이용한면역원성구조체제조
FR2767323B1 (fr) * 1997-08-12 2001-01-05 Synt Em Peptides lineaires derives de peptides antibiotiques, leur preparation et leur utilisation pour vectoriser des substances actives
DE10112825A1 (de) * 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylierung von Wirkstoffen in wässriger Lösung
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
US7538092B2 (en) 2002-10-08 2009-05-26 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
WO2005014655A2 (fr) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugues d'amidon d'hydroxyalkyle et de proteine
KR101863136B1 (ko) 2008-01-24 2018-05-31 에스퍼란스 파마슈티컬스, 인코포레이티드 용해 도메인 융합 구성물 및 이를 제조하고 사용하는 방법
EP2352568B1 (fr) * 2008-10-02 2017-11-29 University of Pittsburgh - Of the Commonwealth System of Higher Education Administration d'un polymère adsorbant pour le traitement d'une inflammation systémique
IL238323B2 (en) 2012-10-30 2023-11-01 Esperance Pharmaceuticals Inc Antibody/drug conjugates and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217956A (en) * 1988-10-21 1993-06-08 The Children's Hospital Of Philadelphia Composition and treatment with biologically active peptides and certain anions
US5221664A (en) * 1990-04-23 1993-06-22 Magainin Pharmaaceuticals Inc. Composition and treatment with biologically active peptides and toxic cations
US5208220A (en) * 1990-06-27 1993-05-04 Magainin Pharmaceuticals, Inc. Composition and treatment with biologically active peptides and antibiotics which inhibit DNA gyrase

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025037729A1 (fr) * 2023-08-14 2025-02-20 건국대학교 산학협력단 Peptide cécropine isolé de larves de trichoplusia ni et son utilisation pour le traitement de la sepsie, d'une infection bactérienne ou de maladies inflammatoires

Also Published As

Publication number Publication date
CA2151046A1 (fr) 1994-06-23
EP0672053A1 (fr) 1995-09-20
AU5741794A (en) 1994-07-04
WO1994013697A1 (fr) 1994-06-23

Similar Documents

Publication Publication Date Title
AU665945B2 (en) Synthetic peptides for detoxification of bacterial endotoxins and treatment of septic shock
JP4044140B2 (ja) インスリン誘導体類とその使用
EP3998077B1 (fr) Molécules de fusion dérivées de la toxine cholix pour l'administration par voie orale d'une charge biologiquement active
RU2139732C1 (ru) Амплификация системы поглощения витамина b12 при помощи полимеров
JPH08504210A (ja) 結合生物活性ペプチドを使用した敗血症性ショックの治療
US20040014652A1 (en) Tumor activated prodrug compounds and methods of making and using the same
JP2019065053A (ja) α−メラニン形成細胞刺激ホルモンのペプチド類似体
JPH10502349A (ja) インテグリンα▲下４▼β▲下１▼のＶＣＡＭ−１またはフィブロネクチンへの結合を阻害する方法
JPH04506664A (ja) 治療用ペプチド
CN1650005B (zh) 抗菌性多肽及其应用
EP1286700A2 (fr) Composes de promedicaments a activation tumorale et procedes de fabrication et d'utilisation de ces derniers
IE83655B1 (en) Synthetic peptides for detoxification of bacterial endotoxins and treatment of septic shock
CA2265476A1 (fr) Conjugues utiles dans le traitement du cancer de la prostate
JP2017002039A (ja) 医薬目的のための新規な多官能性化合物
JP2001512739A (ja) 抗生作用ペプチドから誘導される線状ペプチド、製法および活性物質を仲介する用途
ES2932772T3 (es) Nuevos péptidos grapados y utilizaciones de los mismos
RU2002130203A (ru) Пептидные конъюгаты для доставки лекарственного средства
US20030219854A1 (en) Methods for producing modified anti-infective peptides
CA2150946A1 (fr) Traitement de tumeurs malignes de la peau a l'aide de peptides biologiquement actifs
US5358933A (en) Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock
JPH07501820A (ja) 生物活性ペプチドおよびキレート剤による組成物および治療法
AU693518B2 (en) Ion-channel forming amphiphilic peptides having n-terminal modifications
JPH06504260A (ja) 両親媒性ペプチド組成物及びその類似体
TW201321404A (zh) 加成糖鏈之多胜肽及含有該多胜肽之醫藥組成物
CA2408103A1 (fr) Composes de promedicaments a activation tumorale et procedes de fabrication et d'utilisation de ces derniers